Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorAkşit, Dilek
dc.contributor.authorYalınkılıç, Hande Sultan
dc.contributor.authorSekkin, Selim
dc.contributor.authorBoyacıoğlu, Murat
dc.contributor.authorÇırak, Veli Yilgor
dc.contributor.authorAyaz, Erol
dc.contributor.authorGökbulut, Cengiz
dc.date.accessioned2019-10-17T10:28:11Z
dc.date.available2019-10-17T10:28:11Z
dc.date.issued2015en_US
dc.identifier.urihttps://doi.org/10.1186/s12917-015-0442-5
dc.identifier.urihttps://hdl.handle.net/20.500.12462/8083
dc.descriptionAkşit, Dilek (Balikesir Author)en_US
dc.description.abstractBackground: The aims of this study were to compare the pharmacokinetics of albendazole sulfoxide (ABZ-SO, ricobendazole) in goats and sheep at a dose of 5 mg/kg bodyweight (BW), after intravenous (IV) and subcutaneous (SC) administrations, and to investigate the effects of increased doses (10 and 15 mg/kg BW) on the plasma disposition of ABZ-SO in goats following SC administration. A total of 16 goats (Capra aegagrus hircus, eight males and eight females) and 8 sheep (Ovis aries, four males and four females) 12-16 months old and weighing 20-32 kg, were used. The study was designed according to two-phase crossover study protocol. In Phase-1, eight sheep were assigned as Group I and 16 goats were allocated into two groups (Group II and Group III). ABZ-SO was applied to Group I (sheep) and Group II (goats) animals subcutaneously, and to Group III (goats) animals intravenously, all at a dose rate of 5 mg/kg BW. In Phase-2, the sheep in the Group I received ABZ-SO intravenously in a dose of 5 mg/kg BW; the goats in Group II and Group III received ABZ-SO subcutaneously at a dose of 10 mg/kg and 15 mg/kg BW, respectively. Blood samples were collected from the jugular vein at different times between 1 and 120 h after drug administrations. The plasma concentrations of ABZ-SO and its metabolites were analysed by high performance liquid chromatography. Results: In goats, the area under the curve, terminal half-life and plasma persistence of ABZ-SO were significantly smaller and shorter, respectively, compared with those observed in sheep following both IV and SC administrations at a dose of 5 mg/kg BW. On the other side, dose-dependent plasma dispositions of ABZ-SO were observed following SC administration at increased doses (10 and 15 mg/kg) in goats. Conclusions: Consequently, ABZ-SO might be used at higher doses to provide higher plasma concentration and thus to achieve greater efficacy against the target parasites.en_US
dc.language.isoengen_US
dc.publisherBMCen_US
dc.relation.isversionof10.1186/s12917-015-0442-5en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBenzimidazolesen_US
dc.subjectAlbendazoleen_US
dc.subjectAlbendazole Sulfoxideen_US
dc.subjectPharmacokineticsen_US
dc.subjectEnantiomersen_US
dc.subjectSheepen_US
dc.subjectGoaten_US
dc.titleComparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goatsen_US
dc.typearticleen_US
dc.relation.journalBMC Veterinary Researchen_US
dc.contributor.departmentVeteriner Fakültesien_US
dc.contributor.authorID0000-0003-2811-3579en_US
dc.contributor.authorID0000-0002-4912-7307en_US
dc.contributor.authorID0000-0002-4912-7307en_US
dc.contributor.authorID0000-0002-3795-5375en_US
dc.identifier.volume11en_US
dc.relation.tubitakinfo:eu-repo/grantAgreement/TUBITAK/109 O 862en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster